Multiple-ascending Dose Study With ACT-1014-6470, an Oral Complement Factor 5a Receptor 1 Antagonist, Demonstrated Target Engagement by Ex Vivo Matrix Metalloproteinase 9 Stimulation

Authors
Category Primary study
ConferenceClinical Pharmacology in Drug Development
Year 2022
This article has no abstract
Epistemonikos ID: 4bb6e2a9bbb4f12d6b4a36e5bc9389c2eddc174e
First added on: Apr 30, 2026